136 related articles for article (PubMed ID: 16167021)
1. New molecular insights in myelodysplastic and myeloproliferative disorders.
Emanuel PD
Clin Adv Hematol Oncol; 2005 Jun; 3(6):459-60. PubMed ID: 16167021
[No Abstract] [Full Text] [Related]
2. Mutant molecules of interest in myeloproliferative neoplasms: introduction.
Tefferi A
Acta Haematol; 2008; 119(4):192-3. PubMed ID: 18566535
[No Abstract] [Full Text] [Related]
3. Focus on myeloproliferative diseases and myelodysplastic syndromes.
Van Etten RA; Shannon KM
Cancer Cell; 2004 Dec; 6(6):547-52. PubMed ID: 15607959
[No Abstract] [Full Text] [Related]
4. [Molecular diagnosis of chronic myeloproliferative diseases and myelodysplastic syndromes].
Bock O
Verh Dtsch Ges Pathol; 2007; 91():140-53. PubMed ID: 18314608
[TBL] [Abstract][Full Text] [Related]
5. [Molecular bases of leukemia, MPD and MDS].
Kitamura T
Rinsho Ketsueki; 2009 Mar; 50(3):174-81. PubMed ID: 19352084
[No Abstract] [Full Text] [Related]
6. Bortezomib is an effective agent for MDS/MPD syndrome with 5q- anomaly and thrombocytosis.
Terpos E; Verrou E; Banti A; Kaloutsi V; Lazaridou A; Zervas K
Leuk Res; 2007 Apr; 31(4):559-62. PubMed ID: 16820206
[TBL] [Abstract][Full Text] [Related]
7. Myelodysplastic syndrome evolving into a myeloproliferative disorder: one disease or two?
Verhoef GE; Demuynck H; Zachee P; Boogaerts MA
Leukemia; 1994 Apr; 8(4):714-5. PubMed ID: 8152271
[No Abstract] [Full Text] [Related]
8. Clinicopathological features of unbalanced translocation Der(1;7)(q10;p10) in myeloid neoplasms.
So CC; Ma ES; Wan TS; Yip SF; Chan LC
Leuk Res; 2008 Jun; 32(6):1000-1. PubMed ID: 17980911
[No Abstract] [Full Text] [Related]
9. The myelodysplastic/myeloproliferative disorders: the interface.
Bennett JM
Hematol Oncol Clin North Am; 2003 Oct; 17(5):1095-100, v. PubMed ID: 14560776
[TBL] [Abstract][Full Text] [Related]
10. The cytogenetics of haematological malignancies.
Berger R
Baillieres Clin Haematol; 1992 Oct; 5(4):791-814. PubMed ID: 1308165
[No Abstract] [Full Text] [Related]
11. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
12. Chromosome 20 deletions in myelodysplastic syndromes and Philadelphia-chromosome-negative myeloproliferative disorders: characterization by molecular cytogenetics of commonly deleted and retained regions.
Douet-Guilbert N; Basinko A; Morel F; Le Bris MJ; Ugo V; Morice P; Berthou C; De Braekeleer M
Ann Hematol; 2008 Jul; 87(7):537-44. PubMed ID: 18350294
[TBL] [Abstract][Full Text] [Related]
13. Myeloid malignancies: myelodysplastic syndromes, myeloproliferative disorders, and acute myeloid leukemia.
Wood BL
Clin Lab Med; 2007 Sep; 27(3):551-75, vii. PubMed ID: 17658407
[TBL] [Abstract][Full Text] [Related]
14. A novel chromosomal abnormality involving 2q37 in myeloid malignancies.
Chen CC; Lee KD; Yang CF; Gau JP
Ann Hematol; 2006 May; 85(5):333-4. PubMed ID: 16474975
[No Abstract] [Full Text] [Related]
15. Landscape of RAS pathway mutations in patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a study of 461 molecularly annotated patients.
Buradkar A; Bezerra E; Coltro G; Lasho TL; Finke CM; Gangat N; Carr RM; Binder M; Mangaonkar AA; Ketterling R; Khan S; Rodriguez V; Tefferi A; Patnaik MM
Leukemia; 2021 Feb; 35(2):644-649. PubMed ID: 32513965
[No Abstract] [Full Text] [Related]
16. Myelodysplasia and myeloproliferative disorders in childhood: an update.
Emanuel PD
Br J Haematol; 1999 Jun; 105(4):852-63. PubMed ID: 10554793
[No Abstract] [Full Text] [Related]
17. Association between myeloid malignancies and acquired deficit in protein 4.1R: a retrospective analysis of six patients.
Alanio-Bréchot C; Schischmanoff PO; Fénéant-Thibault M; Cynober T; Tchernia G; Delaunay J; Garçon L
Am J Hematol; 2008 Apr; 83(4):275-8. PubMed ID: 17994571
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of hematologic disorders using a metabolite of vitamin D].
Wilczek H; Neuwirtová R; Pacovský V
Cas Lek Cesk; 1986 Oct; 125(40):1235-8. PubMed ID: 3779773
[No Abstract] [Full Text] [Related]
19. EED mutants impair polycomb repressive complex 2 in myelodysplastic syndrome and related neoplasms.
Ueda T; Sanada M; Matsui H; Yamasaki N; Honda ZI; Shih LY; Mori H; Inaba T; Ogawa S; Honda H
Leukemia; 2012 Dec; 26(12):2557-60. PubMed ID: 22733077
[No Abstract] [Full Text] [Related]
20. [I. Outlook on molecular targeting therapy for myelodysplastic syndrome].
Mitani K
Gan To Kagaku Ryoho; 2012 May; 39(5):732-5. PubMed ID: 22701899
[No Abstract] [Full Text] [Related]
[Next] [New Search]
